Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, ...
PH-762 is a clinical-stage, self-delivering siRNA compound developed using the proprietary INTASYL technology platform. It is engineered to silence the expression of PD-1, a checkpoint protein that inhibits the immune system's ability to attack tumor cells. By reducing PD-1 levels directly within the immune cells, PH-762 aims to reinvigorate the immune response against cancer, specifically targeting conditions like cutaneous Squamous Cell Carcinoma (cSCC).
Pain Points: Addresses the limitations of current cancer therapies, such as the complexity of drug delivery systems (e.g., lipid nanoparticles), potential toxicities, and the inability of the immune system to effectively identify and kill tumor cells due to immune checkpoints.
Solutions: Provides a self-delivering siRNA solution that penetrates cells directly, simplifies administration, reduces toxicity compared to traditional delivery methods, and effectively silences immunosuppressive genes.
Target Users: Patients diagnosed with cancers, specifically cutaneous Squamous Cell Carcinoma (cSCC) and melanoma, in clinical and potential future commercial oncology markets.
Supply Chain
Internal R&D and discoveryThird-party contract manufacturing organizations (CMOs)Clinical research organizations (CROs)Regulatory and clinical trial sites
PH-894 is an INTASYL compound under development in the preclinical stage. It is designed to specifically silence BRD4, a protein known to control gene expression in both T cells and tumor cells. By targeting BRD4, Phio aims to influence the tumor microenvironment and improve the effectiveness of the immune system in attacking tumor cells.
Pain Points: Targets gene expression regulators that contribute to tumor progression and immune system evasion.
Solutions: Offers a method for precise gene silencing using the self-delivering INTASYL platform to impact BRD4 activity, aiming to halt tumor growth and improve immune recognition.
Pyramid Pharma Services, Inc.Unnamed U.S. Drug Substance Manufacturer (Phio Agreement, July 2025)Unnamed U.S. Laboratory (Non-Clinical Toxicology, December 2025)Ethicor Pharma Ltd.Nitto Denko Corp. (parent of Nitto Avecia Pharma Services)TSE:6988Lonza Group AGSWX:LONN
Downstream
7
Gustave Roussy Institute (Institut Gustave Roussy)Banner MD Anderson Cancer CenterGeorge Washington University (GWU) School of Medicine & Health SciencesIntegrity Clinical ResearchParadigm Clinical Research CentersH.C. Wainwright & Co., LLCOPKO Health, Inc.NASDAQ:OPK
